St. Lukes Hospital
- Type
- Teaching hospital
- Where
- SAN FRANCISCO, CA
- Medicare CCN
- 050055
- Received
- $1,205,141 in 120 records, 2020 ($960 general, $1,204,181 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 5 | $960 |
| 2020 | Research payment | 115 | $1,204,181 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 17 | $445,901 | 2020 |
| Edwards Lifesciences Corporation | 37 | $357,215 | 2020 |
| Biogen, Inc. | 5 | $215,253 | 2020 |
| Novartis Pharmaceuticals Corporation | 6 | $85,445 | 2020 |
| CSL Behring | 20 | $54,052 | 2020 |
| Alexion Pharmaceuticals, Inc. | 6 | $13,573 | 2020 |
| BIOTRONIK INC. | 5 | $11,800 | 2020 |
| SK Life Science, Inc. | 13 | $10,508 | 2020 |
| Incyte Corporation | 4 | $8,500 | 2020 |
| Celgene Corporation | 1 | $1,500 | 2020 |
| Zimmer Biomet Holdings, Inc. | 2 | $650 | 2020 |
| NEUROPACE, INC. | 1 | $430 | 2020 |
| Stryker Corporation | 2 | $197 | 2020 |
| GenMark Diagnostics, Inc. | 1 | $112 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 115 | $1,204,181 |
| Gift | 4 | $847 |
| Food and Beverage | 1 | $112 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-23 | Edwards Lifesciences Corporation | $13,080 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2020 | |
| 2020-12-23 | Incyte Corporation | $4,500 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-23 | Incyte Corporation | $1,500 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-23 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-17 | Edwards Lifesciences Corporation | $24,759 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-12-16 | Celgene Corporation | $1,500 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Celgene - Connect MDS/AML | 2020 |
| 2020-12-10 | Edwards Lifesciences Corporation | $650 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | THE ENCIRCLE Trial (#2018-19) | 2020 |
| 2020-12-03 | Alexion Pharmaceuticals, Inc. | $7,000 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-12-03 | Alexion Pharmaceuticals, Inc. | $3,500 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-12-03 | Edwards Lifesciences Corporation | $2,200 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | SM3 Trial 2017-03 | 2020 |
| 2020-12-03 | Alexion Pharmaceuticals, Inc. | $1,200 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-12-03 | Alexion Pharmaceuticals, Inc. | $750 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-12-03 | Alexion Pharmaceuticals, Inc. | $550 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and | 2020 |
| 2020-11-23 | Edwards Lifesciences Corporation | $34,156 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2020 | |
| 2020-11-12 | Novartis Pharmaceuticals Corporation | $750 | Research payment | Cash or cash equivalent | TAFINLAR Drug, ONCOLOGY | COMBIAD A PHASE III RANDOMIZED DOUBLE BLIND STUDY OF DABRAFENIB GSK2118436 IN COMBINATION WITH TRAMETINIB GSK1120212 VER | 2020 |
| 2020-11-11 | CSL Behring | $2,965 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-11 | CSL Behring | $1,428 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-11 | CSL Behring | $1,342 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-11 | CSL Behring | $1,045 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-11 | CSL Behring | $963 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-11 | CSL Behring | $632 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-11 | CSL Behring | $408 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-11 | CSL Behring | $365 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-11 | CSL Behring | $261 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-11 | CSL Behring | $62 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-11 | CSL Behring | $18 | Research payment | In-kind items and services | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-11-10 | SK Life Science, Inc. | $1,653 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 059566 | 2020 |
| 2020-11-10 | CSL Behring | $1,500 | Research payment | Cash or cash equivalent | Haegarda Biological, Immunology | A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri | 2020 |
| 2020-11-10 | CSL Behring | $265 | Research payment | Cash or cash equivalent | Haegarda Biological, Immunology | A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri | 2020 |
| 2020-11-05 | Edwards Lifesciences Corporation | $650 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | SM3 Trial 2017-03 | 2020 |
| 2020-11-05 | E.R. Squibb & Sons, L.L.C. | $121 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Ph III NSCLC 2L, non-squamous | 2020 |
| 2020-11-02 | Edwards Lifesciences Corporation | $837 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2020 | |
| 2020-11-02 | Edwards Lifesciences Corporation | $837 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2020 | |
| 2020-10-28 | Novartis Pharmaceuticals Corporation | $424 | Research payment | Cash or cash equivalent | KISQALI Drug, ONCOLOGY | AN OPEN LABEL MULTICENTER PHASE IIIB STUDY OF RIBOCICLIB LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTM | 2020 |
| 2020-10-26 | Edwards Lifesciences Corporation | $7,037 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2020 | |
| 2020-10-26 | Edwards Lifesciences Corporation | $650 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | THE ENCIRCLE Trial (#2018-19) | 2020 |
| 2020-10-22 | Edwards Lifesciences Corporation | $11,427 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-10-20 | Novartis Pharmaceuticals Corporation | $484 | Research payment | Cash or cash equivalent | PDR001 Biological | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III STUDY COMPARING THE COMBINATION OF PDR001 DABRAFENIB AND TRAMETIN | 2020 |
| 2020-10-19 | Edwards Lifesciences Corporation | $1,500 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | PARTNER3 2015-08 | 2020 |
| 2020-10-19 | Edwards Lifesciences Corporation | $650 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | THE ENCIRCLE Trial (#2018-19) | 2020 |
| 2020-10-08 | Edwards Lifesciences Corporation | $1,000 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | Early-TAVR Trial #2016-07 | 2020 |
| 2020-10-08 | Edwards Lifesciences Corporation | $500 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | Partner3 2015-08 | 2020 |
| 2020-10-05 | Edwards Lifesciences Corporation | $17,000 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | THE ENCIRCLE Trial (#2018-19) | 2020 |
| 2020-10-01 | Edwards Lifesciences Corporation | $22,566 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2020 | |
| 2020-10-01 | Edwards Lifesciences Corporation | $19,053 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2020 | |
| 2020-10-01 | CSL Behring | $7,800 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-10-01 | CSL Behring | $3,250 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-10-01 | CSL Behring | $2,000 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-10-01 | Edwards Lifesciences Corporation | $2,000 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | Early-TAVR Trial #2016-07 | 2020 |
| 2020-10-01 | CSL Behring | $725 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adu | 2020 |
| 2020-09-28 | NEUROPACE, INC. | $430 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | RNS Long Term Trmt Clin Trial | 2020 |
| 2020-09-18 | SK Life Science, Inc. | $1,458 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 59566 | 2020 |
| 2020-09-10 | Edwards Lifesciences Corporation | $2,200 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | SM3 Trial 2017-03 | 2020 |
| 2020-09-10 | Alexion Pharmaceuticals, Inc. | $573 | Research payment | Cash or cash equivalent | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | 2020 | |
| 2020-09-04 | E.R. Squibb & Sons, L.L.C. | $250 | Research payment | Cash or cash equivalent | YERVOY Biological, Oncology | PhIII Adjuvant Melanoma EORTC | 2020 |
| 2020-08-27 | Edwards Lifesciences Corporation | $57,503 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-08-21 | E.R. Squibb & Sons, L.L.C. | $44,470 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Ph IIb 2L Bladder Registrational | 2020 |
| 2020-08-18 | BIOTRONIK INC. | $1,500 | Research payment | Cash or cash equivalent | BioMonitor 2 Device, Cardiology/Vascular Diseases | BIOGUARD-MI | 2020 |
| 2020-08-18 | BIOTRONIK INC. | $500 | Research payment | Cash or cash equivalent | BioMonitor 2 Device, Cardiology/Vascular Diseases | BIOGUARD-MI | 2020 |
| 2020-08-12 | SK Life Science, Inc. | $886 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 59566 | 2020 |
| 2020-07-30 | CSL Behring | $1,653 | Research payment | Cash or cash equivalent | Haegarda Biological, Immunology | A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri | 2020 |
| 2020-07-29 | Novartis Pharmaceuticals Corporation | $22,438 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | PROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF) | 2020 |
| 2020-07-24 | SK Life Science, Inc. | $783 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 59566 | 2020 |
| 2020-07-14 | SK Life Science, Inc. | $572 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 59566 | 2020 |
| 2020-07-09 | Edwards Lifesciences Corporation | $47,560 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2020 | |
| 2020-07-08 | E.R. Squibb & Sons, L.L.C. | $164,058 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Melanoma 2 3L IPI Progressors | 2020 |
| 2020-07-02 | Edwards Lifesciences Corporation | $22,035 | Research payment | Cash or cash equivalent | PARTNER3 2015-08 | 2020 | |
| 2020-06-18 | Edwards Lifesciences Corporation | $2,175 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2020 | |
| 2020-06-16 | BIOTRONIK INC. | $50 | Research payment | Cash or cash equivalent | BioMonitor 2 Device, Cardiology/Vascular Diseases | BIOGUARD-MI | 2020 |
| 2020-06-11 | Edwards Lifesciences Corporation | $500 | Research payment | Cash or cash equivalent | Trial #2017-18 ExCEED | 2020 | |
| 2020-06-08 | E.R. Squibb & Sons, L.L.C. | $5,363 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Nivo ipi vs Nivo in Stage IIIb c or IV Adjuvant Melanoma | 2020 |
| 2020-06-01 | Biogen, Inc. | $458 | Research payment | In-kind items and services | Methodology Study of Novel Outcome Measures to Assess Progression of ALS | 2020 | |
| 2020-06-01 | SK Life Science, Inc. | $455 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 1-FA7759 | 2020 |
| 2020-05-27 | SK Life Science, Inc. | $1,027 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 1-FA7759 | 2020 |
| 2020-05-19 | E.R. Squibb & Sons, L.L.C. | $42,076 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Ph III registrational study in 1L HCC nivo monotherapy | 2020 |
| 2020-05-15 | SK Life Science, Inc. | $810 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 1-FA7759 | 2020 |
| 2020-05-13 | E.R. Squibb & Sons, L.L.C. | $16,838 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III NSCLC 1L combo | 2020 |
| 2020-05-08 | E.R. Squibb & Sons, L.L.C. | $6,054 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase II 1L Mel - IPI Combo | 2020 |
| 2020-05-07 | SK Life Science, Inc. | $14 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 1-FA7759 | 2020 |
| 2020-04-30 | Stryker Corporation | $114 | Gift | In-kind items and services | ULTRA COMFORT SURFACE Device, PATIENT HANDLING - PH | 2020 | |
| 2020-04-30 | Stryker Corporation | $82 | Gift | In-kind items and services | ULTRA COMFORT SURFACE Device, PATIENT HANDLING - PH | 2020 | |
| 2020-04-28 | Edwards Lifesciences Corporation | $2,825 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | PARTNER3 2015-08 | 2020 |
| 2020-04-24 | GenMark Diagnostics, Inc. | $112 | Food and Beverage | In-kind items and services | ePlex Device, Devices | 2020 | |
| 2020-04-23 | Edwards Lifesciences Corporation | $1,390 | Research payment | Cash or cash equivalent | Early Feasibility Study of the CardiAQ Transcatheter Mitral Valve Implantation (TMVI) System 2013-05C | 2020 | |
| 2020-04-20 | Zimmer Biomet Holdings, Inc. | $0 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2020 | |
| 2020-04-16 | CSL Behring | $769 | Research payment | Cash or cash equivalent | Haegarda Biological, Immunology | A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri | 2020 |
| 2020-04-15 | Zimmer Biomet Holdings, Inc. | $650 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2020 | |
| 2020-04-14 | Incyte Corporation | $1,500 | Research payment | Cash or cash equivalent | A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome | 2020 | |
| 2020-04-09 | Edwards Lifesciences Corporation | $34,917 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-04-08 | E.R. Squibb & Sons, L.L.C. | $6,355 | Research payment | Cash or cash equivalent | Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix (Belatac | 2020 | |
| 2020-04-01 | SK Life Science, Inc. | $1,830 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 1-FA7759 | 2020 |
| 2020-04-01 | Novartis Pharmaceuticals Corporation | $1,778 | Research payment | Cash or cash equivalent | KISQALI Drug, ONCOLOGY | RIBOCICLIB + STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR+HER2-EARLY BC AT HIGH RISK FOR RECURRENCE | 2020 |
| 2020-04-01 | SK Life Science, Inc. | $143 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 1-FA7759 | 2020 |
| 2020-03-24 | BIOTRONIK INC. | $250 | Research payment | Cash or cash equivalent | BioMonitor 2 Device, Cardiology/Vascular Diseases | BIOGUARD-MI | 2020 |
| 2020-03-18 | Edwards Lifesciences Corporation | $1,500 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | PARTNER3 2015-08 | 2020 |
| 2020-03-17 | BIOTRONIK INC. | $9,500 | Research payment | Cash or cash equivalent | BioMonitor 2 Device, Cardiology/Vascular Diseases | BIOGUARD-MI | 2020 |
| 2020-03-09 | E.R. Squibb & Sons, L.L.C. | $28,758 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Monotherapy | 2020 |
| 2020-03-09 | Edwards Lifesciences Corporation | $7,212 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2020 | |
| 2020-03-06 | Edwards Lifesciences Corporation | $1,337 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2020 | |
| 2020-03-04 | Edwards Lifesciences Corporation | $8,615 | Research payment | Cash or cash equivalent | Early Feasibility Study of the CardiAQ Transcatheter Mitral Valve Implantation (TMVI) System 2013-05C | 2020 | |
| 2020-03-03 | SK Life Science, Inc. | $91 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects with Partial O | 2020 |
| 2020-03-02 | Biogen, Inc. | $2,700 | Research payment | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy | 2020 |
| 2020-02-25 | Edwards Lifesciences Corporation | $1,000 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | Early-TAVR Trial #2016-07 | 2020 |
| 2020-02-20 | E.R. Squibb & Sons, L.L.C. | $11,402 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant HCC mono vs placebo | 2020 |
| 2020-02-18 | CSL Behring | $26,595 | Research payment | In-kind items and services | Berinert Biological, Immunology | A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri | 2020 |
| 2020-02-12 | Edwards Lifesciences Corporation | $837 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2020 | |
| 2020-02-05 | E.R. Squibb & Sons, L.L.C. | $27,097 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Stage II B C Opdivo Mono | 2020 |
| 2020-02-05 | Edwards Lifesciences Corporation | $650 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | SM3 Trial 2017-03 | 2020 |
| 2020-02-04 | Biogen, Inc. | $87,835 | Research payment | Cash or cash equivalent | Long-Term Evaluation of BIIB067 | 2020 | |
| 2020-02-03 | SK Life Science, Inc. | $783 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects with Partial O | 2020 |
| 2020-01-31 | Edwards Lifesciences Corporation | $2,200 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | SM3 Trial 2017-03 | 2020 |
| 2020-01-29 | Edwards Lifesciences Corporation | $2,200 | Research payment | Cash or cash equivalent | Early Feasibility Study of the CardiAQ Transcatheter Mitral Valve Implantation (TMVI) System 2013-05C | 2020 | |
| 2020-01-27 | E.R. Squibb & Sons, L.L.C. | $36,847 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF2 | 2020 | |
| 2020-01-27 | E.R. Squibb & Sons, L.L.C. | $30,847 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF2 | 2020 | |
| 2020-01-22 | Novartis Pharmaceuticals Corporation | $59,571 | Research payment | Cash or cash equivalent | PDR001 Drug | MODULAR PHASE 2 STUDY TO LINK COMBINATION IMMUNE THERAPY TO PATIENTS WITH ADVANCED SOLID AND HEMATOLOGIC MALIGNANCIES MO | 2020 |
| 2020-01-21 | E.R. Squibb & Sons, L.L.C. | $21,431 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Nivo Ipi vs Placebo in Adjuvant RCC | 2020 |
| 2020-01-21 | Biogen, Inc. | $7,348 | Research payment | Cash or cash equivalent | PLEGRIDY Biological, NEUROLOGY | Plegridy Observational Program | 2020 |
| 2020-01-21 | E.R. Squibb & Sons, L.L.C. | $1,856 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Bladder nivo mono | 2020 |
| 2020-01-06 | E.R. Squibb & Sons, L.L.C. | $2,071 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Study Adj GEJ & Esoph US EU mono | 2020 |
| 2020-01-01 | Biogen, Inc. | $116,912 | Research payment | Cash or cash equivalent | An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyot | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Francisco, CA | County San Francisco County, CA | State California |
|---|---|---|---|
| Population B01003 | 830,235 | 830,235 | 39,287,377 |
| Population, 2020 census P1 | 873,965 | 873,965 | 39,538,223 |
| Median age B01002 | 40.0 | 40.0 | 37.9 |
| Under 18 B01001 | 13.7% | 13.7% | 22.0% |
| 65 and over B01001 | 17.6% | 17.6% | 15.7% |
| Households B11001 | 363,970 | 363,970 | 13,548,091 |
| Foreign born B05002 | 34.0% | 34.0% | 27.0% |
| Median household income B19013 | $140,970 | $140,970 | $99,122 |
| Median family income B19113 | $171,141 | $171,141 | $113,346 |
| Per capita income B19301 | $92,289 | $92,289 | $49,513 |
| Poverty rate B17001 | 11.2% | 11.2% | 12.0% |
| Unemployment rate B23025 | 6.1% | 6.1% | 6.6% |
| Civilian labor force B23025 | 507,262 | 507,262 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 60.3% | 60.3% | 37.1% |
| Housing units B25001 | 414,602 | 414,602 | 14,644,735 |
| Owner-occupied B25003 | 38.2% | 38.2% | 55.9% |
| Renters B25003 | 61.8% | 61.8% | 44.1% |
| Median home value B25077 | $1,394,500 | $1,394,500 | $734,700 |
| Median gross rent B25064 | $2,476 | $2,476 | $2,036 |
| White, not Hispanic B03002 | 36.8% | 36.8% | 33.8% |
| Black B03002 | 4.7% | 4.7% | 5.2% |
| Hispanic or Latino B03002 | 16.2% | 16.2% | 40.2% |
| Asian B03002 | 34.9% | 34.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.
Comments